Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Giant King Grass is considered a renewable and environmentally friendly alternative to fossil fuels. Burning grass or a biofuel made from grass releases carbon dioxide into the atmosphere. However the next crop of grass 60 days later absorbs the carbon dioxide during its growth and the process can be carbon neutral over a 60 day growing cycle. Additional carbon dioxide can be released by the trucks that transport the grass and the processes used to make the biofuel. If these are carefully managed, Giant King Grass can be a very low carbon fuel source.
Well so it was always with Via.
News related only to progress but never for profit.
DMFC heard nothing more, what about Samsung?
Said that 2008 was harvested 4 times 2009 now they have only harvested once. And the amount we do not know!
Fir
In Germany, nobody buys because of this news!
Not even the MM Taxt higher!
Nothing will happen!
Fir!
There was no mention of 4 times per year, the harvest?
How much did you harvest when the tests are finished?
The course is the news does not really care!
What we need sales income results and win!
Everything else is a hope and nothing else.
I've been in 3 years via a number of shares and no news has been able to Via steadily increased but only to please.
Patience is what you need here!
Fir
First Giant King Grass Harvest
2009-12-02 08:30 ET - News Release
IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- VIASPACE Inc. , a clean energy company growing Giant King(TM) Grass as a renewable, low-carbon energy crop, today announced that the first harvest of Giant King Grass has been completed and that a new grass processing and storage facility is under construction on company land in China.
Chief Executive Dr. Carl Kukkonen stated: "The grass from this harvest provided seedlings for planting on our new land and is also being used to supply samples for testing and analysis by potential customers such as DP CleanTech and other electric power providers. The new building, now under construction, will process Giant King Grass into pellets and other biomass products, as well as prepare seedlings for the planned expansion of planted acreage."
According to Kukkonen, a new independent analysis in Europe verified that Giant King Grass has excellent energy content (19.2 megajoules per dry kilogram, or 4,585 kilocalories per kilogram-- slightly higher than previous measurements). And the fast-growing nature of Giant King Grass means it is a highly productive and economically advantageous crop, compared to all other biomass crops. Furthermore, Giant King Grass can be harvested in the first year, whereas many other energy crops cannot be harvested until they have been growing for two or more years. "We feel these characteristics together make Giant King Grass very attractive to biomass users, and we are seeing evidence of that in the form of requests for proposals, sales inquiries and MOUs," he said.
Kukkonen gave a presentation on Giant King Grass at the Next-Generation Biofuels Feedstocks USA Conference held November 16-17, 2009, at Le Meridien Hotel in San Francisco. The presentation--with pictures of the harvest, new land and building--is available at the bottom right of the home page of VIASPACE's website www.VIASPACE.com.
A follow-up interview with Kukkonen was published on November 23, 2009, by the DTN Ethanol Center. The interview is available at the bottom of the home page and may be accessed directly at http://www.dtnethanolcenter.com/index.cfm?show=10&mid=83&pid=37 .
Prior to the presentation and interview, Kukkonen was on a three-week trip to Asia, where he visited the Company's grass lands and met with current and potential partners and customers.
IRVINE, Kalifornien, November 30 - VIASPACE Inc. (OTC Bulletin Board: VSPC), einer sauberen Energie-Unternehmen wächst Giant King (TM) Grass als einer kohlenstoffarmen, erneuerbare Energien Ernte, gab heute bekannt, dass am 25. November 2009 Es reichte einen geänderten Formular S-1 bei der Securities and Exchange Commission ihre Mehrheit Liste Tochtergesellschaft VIASPACE Green Energy Inc. (VGE), als separat Berichterstattung Aktiengesellschaft. Die geänderte Anmeldung ist verfügbar unter www.SEC.gov VIASPACE Green Energy.
Die Stammaktien von VGE wird erwartet, dass auf dem OTC Bulletin Board gehandelt werden. VIASPACE Inc. geht davon aus, dass die Mehrheit an der VIASPACE Green Energy, der laufenden Verwaltung und des Betriebs von VGE und VGE Fokus auf erneuerbare Energien unverändert bleibt.
VIASPACE CEO Carl Kukkonen bekräftigte, dass mit einer gesonderten Berichterstattung, VGE-Geschäft, das Wachstumspotenzial und finanziellen Fortschritte besser sichtbar werden und bieten Investoren einen besseren Einblick in die VGE als Investitionsmöglichkeit in erneuerbare Energien. Seit VIASPACE Inc. wird seine Mehrheitsbeteiligung im Eigentum der VGE, VIASPACE Inc. Aktionäre können von der voraussichtlichen Geschäftsentwicklung VGE Wachstum und Wertsteigerung profitieren zu behalten.
Die S-1 Ablage, wirksame Eintragung der SEC und der Austausch-Listing der Stammaktien von VGE erfüllen auch eine Bedingung für die zweite Schließung der 21. Oktober 2008, den Erwerb von Inter-Pacific Arts (IPA). VIASPACE Inc. ist in den Verhandlungen mit dem Verkäufer der IPA den zweiten Abschluss Wirkung, und die Frist für die zweite Schließung wurde von 26. November 2009 verlängert, bis zum 15. Dezember 2009.
Urigen Announces Positive Phase II Clinical Trial Results with URG101
URG101 Significantly Reduces Painful Bladder Syndrome/Interstitial Cystitis Symptoms Following A Single Dose
BURLINGAME, Calif., Mar 12, 2008 (BUSINESS WIRE) -- Urigen Pharmaceuticals, Inc. (OTCBB: URGP), http://www.urigen.com, today announced positive results from a multi-center, double-blind, placebo-controlled, crossover designed clinical trial of URG101 in patients with Painful Bladder Syndrome / Interstitial Cystitis (PBS/IC)
"Urigen is pleased to announce these positive results from our URG101-104 Phase II trial. We believe this data confirms earlier studies and demonstrates URG101 significantly reduces PBS/IC symptoms following a single dose of the product. First dose symptom relief can be important for many patients that experience periods of acute symptom exacerbation" stated Dennis Giesing, PhD, Chief Scientific Officer of Urigen Pharmaceuticals.
URG101 Phase II Trial Results
URG101, an investigational bladder instillation, is a proprietary pharmaceutical treatment comprised of lidocaine and heparin. This Phase II study was a multi-center, double-blind, randomized, placebo-controlled, cross-over study comparing URG101 to placebo. The results reported today are based upon an interim analysis of 21 completed patients. The trial design allows up to 50 patients to be enrolled in the study. Additional analyses are ongoing, the results of which will become available over the next weeks at which time a decision will be made regarding enrollment of additional patients. Primary and secondary efficacy measurements in the study demonstrated that URG101 was significantly better than placebo. Top line data analysis findings include:
-- Primary Endpoint - Improvement in Average Daytime Pain (p=0.03).
-- Secondary Endpoints - Improvement in Daytime Urgency (p=0.03) and Total Symptom Score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by PORIS (p=0.01).
About Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)
Painful Bladder Syndrome/Interstitial Cystitis is a recognized medical condition with increased frequency of diagnosis. PBS/IC is characterized by bladder pain, urinary urgency and nocturia where few IC treatments exist and no approved therapies are available for PBS. Today, there are an estimated 10.5 million women and men in North America who suffer from PBS/IC.
Urigen will conduct a live webcast to provide a complete review of the Company's development programs at 11:00 a.m. EST on Thursday, March 13, 2008. To access an audio webcast of this event, please go to the link on Urigen's website at http://www.urigen.com five minutes in advance of the start time. Questions will be taken by email during the live webcast. A replay will also be available on demand, starting four hours after the webcast's conclusion and until March 31, 2008.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. URG201 targets male hypogonadism, which has been estimated to effect 13 million men in the United States. Urigen's URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.
SOURCE: Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, 650-259-0239
Chief Financial Officer
www.urigen.com
or
Thomas Redington
203-222-7399
212-926-1733
www.redingtoninc.com
Urigen gibt positive klinische Phase II Studie Ergebnisse mit URG101
URG101 Deutlich verringert Painful Bladder Syndrome / Interstitial Cystitis Symptome nach einer Einzeldosis
Burlingame, Kalifornien, 12. März 2008 (BUSINESS WIRE) - Urigen Pharmaceuticals, Inc. (OTCBB: URGP), http://www.urigen.com, heute positive Ergebnisse einer multizentrischen, doppelblinden, Placebo-kontrollierte, Crossover entwickelt klinischen Studie der URG101 bei Patienten mit schmerzhaften Blasen-Syndrom / Interstitielle Cystitis (PBS / IC)
"Urigen freut sich, diese positiven Ergebnisse aus unserer URG101-104 Phase-II-Studie bekannt zu geben. Wir glauben, dass diese Daten bestätigen frühere Studien und zeigt URG101 deutlich reduziert PBS / IC-Symptome nach einer einzelnen Dosis des Produktes. Erste Dosis Linderung der Symptome kann wichtig sein für viele Patienten, dass die Erfahrungen Zeiten der akuten Exazerbation Symptom ", sagte Dennis Giesing, PhD, Chief Scientific Officer von Urigen Pharmaceuticals.
URG101 Phase II-Studie
URG101, ein in der Erforschung Blase Instillation, ist eine proprietäre pharmazeutische Behandlung von Lidocain und Heparin zusammen. Diese Phase-II-Studie war eine multizentrische, doppelblinde, randomisierte, placebo-controlled, cross-over Studie URG101 Vergleich zu Placebo. Die berichteten Ergebnisse sind heute auf eine vorläufige Analyse der 21 Patienten der Grundlage abgeschlossen. Das Studiendesign ermöglicht bis zu 50 Patienten in die Studie aufgenommen werden. Weitere Auswertungen werden zurzeit durchgeführt, deren Ergebnisse werden im Laufe der nächsten Wochen zur Verfügung zu welchem Zeitpunkt wird eine Entscheidung über die Einschreibung von zusätzlichen Patienten vorgenommen werden. Primäre und sekundäre Wirksamkeit Messungen in der Studie zeigten, dass URG101 signifikant besser als Placebo. Top Datenanalyse Ergebnisse:
- Primärer Endpunkt - Verbesserung der durchschnittlichen Tages-Pain (p = 0,03).
- Sekundäre Endpunkte - Verbesserung der Daytime Dringlichkeit (p = 0,03) und Total Symptom Score (p = 0,03). Darüber hinaus berichteten die Patienten verbessert Linderung der Symptome mit URG101 wie PORIS gemessen (p = 0,01).
Über Painful Bladder Syndrome / Interstitial Cystitis (PBS / IC)
Schmerzhafte Blasen-Syndrom / interstitielle Zystitis ist eine anerkannte Krankheit mit zunehmender Häufigkeit der Diagnose. PBS / IC wird durch Blasenschmerzen gekennzeichnet, Harndrang und Nykturie, wo nur wenige IC-Behandlungen und gibt es keine zugelassenen Therapien für PBS zur Verfügung. Heute gibt es schätzungsweise 10,5 Millionen Frauen und Männer in Nordamerika, die von PBS leiden / IC.
Urigen wird ein Live-Webcast, eine vollständige Überprüfung der Entwicklung des Unternehmens-Programme bieten Verhalten um 11:00 Uhr EST am Donnerstag, 13. März 2008. Um einen Audio-Webcast der Veranstaltung Zugang, bitte den Link auf der Website Urigen gehen auf http://www.urigen.com fünf Minuten vor der Startzeit. Die Fragen werden per E-Mail während der Live-Übertragung ergriffen werden. Eine Aufzeichnung wird auch auf Nachfrage zur Verfügung, beginnend vier Stunden nach Abschluss des Webcast und bis zum 31. März 2008.
Über Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals ist ein spezialisiertes Pharmaunternehmen für die Entwicklung und Kommerzialisierung von therapeutischen Produkten für urologische Erkrankungen gewidmet. Urigen der Entwicklung seiner Produkte Programme Ziel mit hohem medizinischem Bedarf und wichtige Marktchancen in der Urologie. URG101 Ziele schmerzhafte Blasen-Syndrom / interstitielle Zystitis, die rund 10,5 Millionen Männer und Frauen in Nordamerika beeinflusst. URG201 Ziele männlichem Hypogonadismus, die Schätzungen auf 13 Millionen Menschen in den Vereinigten Staaten Wirkung. Urigen's URG301 Projekt zielt auf Urethritis und akute Dringlichkeit bei Patienten mit einer überaktiven Blase diagnostiziert. Für weitere Informationen, besuchen Sie bitte die Website Urigen's bei http://www.urigen.com.
Forward-Looking Statement
Diese Pressemitteilung enthält möglicherweise zukunftsgerichtete Aussagen. In einigen Fällen können Sie kennzeichnen solche vorausschauenden Aussagen durch Begriffe wie "könnte", "" will, "" should, "" erwarten, vorhersagen, "" plan, "" anticipate, "" believe, "" estimate, "", "," potenziell "oder" fortführen ", die Verneinung dieser Ausdrücke oder vergleichbare Terminologie. Diese Aussagen sind nur Prognosen. Obwohl wir glauben, dass die Erwartungen, die in den vorausschauenden Aussagen realistisch sind, sollten diese Aussagen nicht als eine Repräsentation durch die Gesellschaft oder eine andere Person aufgefasst werden, dass solche vorausschauenden Aussagen erreicht werden reflektiert. Wir übernehmen keine Verpflichtung, alle von den zukunftsbezogenen Aussagen zu aktualisieren, ob als Ergebnis neuer Informationen, zukünftiger Ereignisse oder anderweitig. In Anbetracht der vorstehenden Ausführungen sind Leser sollte daher nicht unangemessen auf diese zukunftsgerichteten Aussagen zu verlassen. Für weitere Risikofaktoren, die mit unserem Unternehmen verbunden sind, lesen Sie bitte unsere Unterlagen bei der SEC.
QUELLE: Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, 650-259-0239
Chief Financial Officer
www.urigen.com
oder
Thomas Redington
203-222-7399
212-926-1733
www.redingtoninc.com
Viaspace Cultivating High-Biomass Grass 11/23/09 11:42:19 AM Printer Friendly VersionPrinter Friendly Version
Free DTN Ethanol Newsletter
Stay on top of the Ethanol Industry’s latest news by signing up for the DTN Ethanol Newsletter.
Enter your email address to subscribe.
By Todd Neeley
DTN Staff Reporter
OMAHA (DTN) -- Viaspace could be a sleeping giant waiting for U.S. power plants and cellulosic ethanol producers to get their act together.
Right now the Irvine, Calif., company, which went public in 2005, is carving out a niche in the biomass-to-energy business.
Viaspace is developing a crop in subtropical areas of southern China that it calls "Giant King Grass" -- a high-biomass dynamo that contains two-and-a-half times more energy than switchgrass.
Viaspace CEO, Chairman and co-founder Carl Kukkonen said the company is teaching Chinese farmers to grow the crop near a 30-megawatt power plant that uses biomass instead of coal.
"In China and around the world there are a lot of biomass electricity plants," he said, "and zero cellulosic ethanol plants."
He said the U.S.'s limitation on ethanol blends to E10 in standard vehicles means there is little demand for cellulosic ethanol, leading the company to concentrate its efforts offshore. Ethanol advocacy group Growth Energy has petitioned the U.S. Environmental Protection Agency to allow E15.
Viaspace concentrates on growing, harvesting and processing King Grass into dense pellets that are burned by power plants. It's growing the biomass on about 250 acres.
In a news release this week, Viaspace said it believes it can develop up to 25,000 planted acres of King Grass. Included in this plan are potential projects for 2010 involving 5,000 acres that would produce about 200,000 tons of King Grass pellets that could be sold for about $20 million.
US Power Plants not Part of Market
Kukkonen said because the U.S. didn't sign the Kyoto protocol, U.S. power plants aren't required to use biomass, so there's little or no U.S. market although several states have renewable energy requirements prompting coal plants to burn biomass.
In China, however, he said the government not only buys power from biomass power plants, but it provides subsidies for the production of that power.
Viaspace is banking on the U.S. government to head in the same direction.
"We think it's a matter of time," Kukkonen said. "We believe it's going to be big, and we want to be positioned when it happens. Most (U.S.) utilities are not happy to have offtake agreements with biomass companies."
Viaspace is working with DP Cleantech, which has built 19 biomass power plants in China.
King Grass Could Grow in Cooler Climates
DTN Agronomist Dan Davidson said the scientific name for Giant King Grass is Pennisetum genus, which is related to elephant grass.
In southern China, Kukkonen said, King Grass grows to be 12 to 15 feet. Although the species is best suited for tropical and subtropical climates, he said the company would consider growing the crop in cooler areas of the U.S.
King Grass could be grown from May to November in the cooler regions of the Corn Belt. However, Kukkonen said it would require replanting every year because the colder climate would kill the plant. In warmer climates, the plant is perennial, although Kukkonen recommends replanting every seven or eight years. If Viaspace makes an entry into the U.S. at some point, he said it would be in the South and Southeast where sugarcane is grown.
"If you can rotate with a legume where you can fix nitrogen," Kukkonen said, "it would be a perfect scenario -- soybeans for a few years then rotate back."
DTN's Dan Davidson said King Grass would be tough to include in the typical corn-soybean rotation in the Corn Belt, but not impossible.
"It won’t fit well into a corn and soybean rotation," he said. "It is not adapted to cooler, temperate climates like miscanthus or switchgrass. But generally these species like poor and marginal soils where crops don’t fare so well.
"But (in) the U.S. it could have dual purposes, pelleted for coal fire plants or baled and ground and digested for ethanol. It will have all the characteristics of switchgrass, miscanthus and other grass species for cellulosic conversion. However, it will be adapted to different environments and that is a good thing."
In the second year of growing King Grass, Kukkonen said it could be harvested at three feet high every three months. It has the ability to produce about 71 tons of biomass per acre. If harvested continuously King Grass typically needs to be replanted, he said.
"It uses much less fertilizer than corn and is grown as an energy crop," Kukkonen said. "You're not linked to the food-ripening cycle and can harvest continuously."
When it's first planted the King Grass plant needs to be weeded, and it needs about 32 inches of water and more than 100 days of sun per year, he said. As a result King Grass would be most suitable for warmer, wetter U.S. regions.
It is not an invasive species, Kukkonen said. The company will propagate seedlings by division. He said planting is as simple as digging a hole, dropping in the seedling, covering it up, fertilizing and watering. It's almost like planting a flower garden.
In China, a 30-megawatt power plant requires about 600 tons of King Grass each day. Kukkonen said when the crop is harvested it contains 60 to 65 percent moisture. Then, it can be laid in a field for 10 days to dry down to about 25 percent. At that point, he said it is similar in texture to corn stover.
In China, Kukkonen said his company can produce the grass for about $20 a ton at 25 percent moisture. He said U.S. farmers could probably get anywhere from $36 to $80 a ton for the King Grass, sold either to a biomass power plant or a cellulosic ethanol plant.
He said the company isn't willing to start growing the grass without an agreement with a power plant. So getting started in the United States would require a 30-megawatt biomass-using power plant and about 3,500 acres to grow King Grass.
"You can haul the stuff to a power plant cut to two feet in length," Kukkonen said. "You don't have to bale or store it. We'd like to get a farmer going in the U.S."
Todd Neeley can be reached at todd.neeley@dtn.com. Copyright 2009 DTN/The Progressive Farmer- A Telvent brand. All rights reserved.
VIASPACE Update auf VIASPACE Green Energy IPO
2009-11-23 08:30 ET - News Release
IRVINE, Kalifornien, November 23 / PRNewswire / - VIASPACE Inc., ein sauberer Energieträger wachsenden Unternehmen Giant King (TM) Grass als einer kohlenstoffarmen, erneuerbare Energien Ernte, gab heute ein Update über den Status des ursprünglichen Börsengang seiner Tochtergesellschaft im Mehrheitsbesitz VIASPACE Green Energy.
VIASPACE Green Energy (VGE) eingereichten Registration Statement auf Formblatt S-1 bei der Securities and Exchange Commission (SEC) auf Aktien für die öffentlichen Kassen. VGE gingen Stellungnahmen von der SEC eingereicht und einen geänderten S-1 am 19. November 2009. Es ist auf der Website der SEC www.SEC.gov unter dem Firmennamen VIASPACE Green Energy.
VIASPACE CEO Dr. Carl Kukkonen erklärte: "Wir sind sehr optimistisch, dass die Registrierung und Verlustrechnung für VIASPACE Green Energy angenommen wird."
Gemäß den Bestimmungen des Wertpapiererwerbs-Übereinkommen vom 21. Oktober 2009 und deren Änderungen, VIASPACE ist verpflichtet, 4,8 Millionen Dollar in bar zuzüglich Zinsen an den Verkäufer zahlen, um die zweite und die letzte Wirkung. Die Frist für die zweite Schließung ist bis zum 26. November 2009 verlängert. VIASPACE ist in aktiven Verhandlungen mit dem Verkäufer.
Über VIASPACE Inc.
Viaspace, Rentech to present at Pacific West Biomass Conference & Expo
By Anna Austin
Posted November 20, 2009, at 11:44 a.m. CST
Carl Kukkonen, CEO of Viaspace Inc., and Michael Fatigati, director of biomass business development for Rentech Inc., will be presenting at the Pacific West BIOMASS Conference & Expo., the first of a series of regional biomass events that Biomass Magazine is sponsoring in 2010.
The conference and expo will be held Jan. 11-13 at the Hyatt Regency in Sacramento, Calif., and will focus on biomass utilization in California, Oregon, Washington, Idaho and Nevada. The conference will feature more than 60 speakers organized into 18 panels.
Kukkonen will appear on the panel called Feedstocks for Next Generation Biofuels and will inform conference attendees about Viaspace, which holds a worldwide license to grow and cultivate Giant China King Grass, a fast-growing perennial plant that can grow nearly four meters in 60 days and can be harvested four times a year, producing yields of up to 156 metric tons (172 tons) per acre.
The company currently has more than 1 million seedlings on 112 acres in the Guangdong Province in southern China, and recently signed a memorandum of understanding with Beijing-based biomass power provider DP Cleantech to supply the grass for testing at a 30-megawatt power plant.
Article Continues After Advertisement
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Kukkonen will be joined by Fatigati, who will detail Rentech’s biomass gasification process, which can convert multiple biomass feedstocks into synthesis gas for production of renewable fuels and power. The company is currently developing a renewable synthetic diesel plant in Rialto, Calif. Rentech also has an alliance with Honeywell’s UOP LLC to combine technologies for a solution to produce synthetic fuels from biomass feedstocks.
Dallas Hanks of FreeWays to Fuels and Scott Johnson, president of Sustainable Oils Scott Johnson will complete this panel.
“Delivering massive quantities of biomass to refineries for power production has proven to be quite a challenge with a number of considerations that need to be made,” said Tim Portz, BBI International program manager. “The speakers on this panel are taking a number of different approaches to solve that problem.”
Conference attendees will also have the opportunity to visit an operating biomass power facility, a wastewater treatment plant capturing and utilizing biogas, and a private technology development laboratory housing multiple biomass technologies in various stages of development.
To register or to see the agenda for the Pacific Northwest Biomass Conference & Expo, go to http://pacificwest.biomassconference.com.
Biomass Magazine is also holding the 2010 International BIOMASS Conference & Expo May 4-6 in Minneapolis. To find out more about this conference, visit the Web sit at www.biomassconference.com.
In ten Minutes we are falling to 0,023 ..
No Volumen ...
Greetings
Also erstmal Geld kostet, so wird es erstmal weiter unten, ich glaube, wir werden sehr schnell die 0,02 sehen.
Hier müssen wir Einkommen und Ertrag!
Solange dies nicht geschieht, wird es keine Preiserhöhung!
Begrüßung
Hallo aus Deutschland
Form 10-Q for URIGEN PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
16-Nov-2009
Quarterly Report
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "projects," "will," and other words of similar import or the negative of those terms or expressions. Forward-looking statements in this section include, but are not limited to, expectations of future levels of research and development spending, general and administrative spending, levels of capital expenditures and operating results, sufficiency of our capital resources our intention to pursue and consummate strategic opportunities available to us, including sales of certain of our assets. Forward-looking statements subject to certain known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Part I, "Item 1A. Risk Factors" of 10-K reports filed with the Securities and Exchange Commission and those described from time to time in our future reports filed with the Securities and Exchange Commission.
CORPORATE OVERVIEW
We were formerly known as Valentis, Inc. and were formed as the result of the merger of Megabios Corp. and GeneMedicine, Inc. in March 1999. We were incorporated in Delaware on August 12, 1997. In August 1999, we acquired U.K.-based PolyMASC Pharmaceuticals plc.
On October 5, 2006, we entered into an Agreement and Plan of Merger, as subsequently amended (the "Merger") with Urigen N.A., Inc., a Delaware corporation ("Urigen N.A."), and Valentis Holdings, Inc., our newly formed wholly-owned subsidiary ("Valentis Holdings"). Pursuant to the Merger Agreement, on July 13, 2007, Valentis Holdings was merged with and into Urigen N.A., Inc. with Urigen N.A., Inc. surviving as our wholly-owned subsidiary. In connection with the Merger, each Urigen stockholder received, in exchange for each share of Urigen N.A. common stock held by such stockholder immediately prior to the closing of the Merger, 2.2554 shares of our common stock. At the effective time of the Merger, each share of Urigen N.A Series B preferred stock was exchanged for 11.277 shares of our common stock. An aggregate of 51,226,679 shares of our common stock were issued to the Urigen N.A. stockholders. Upon completion of the Merger, we changed our name from Valentis, Inc. to Urigen Pharmaceuticals, Inc. (the "Company").
From and after the Merger, our business is conducted through our wholly owned subsidiary Urigen N.A. The discussion of our business in this annual report is that of our current business which is conducted through Urigen N.A.
We are located in San Francisco, California, where our headquarters and business operations are located.
BUSINESS OVERVIEW
We specialize in the development of innovative products for patients with urological ailments including, specifically, the development of innovative products for amelioration Painful Bladder Syndrome/Interstitial Cystitis ("PBS" or "PBS/IC"), Urethritis, Nocturia and Overactive Bladder ("OAB").
Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS. Many of these indications represent significant, underserved therapeutic market opportunities.
Over the next several years a number of key demographic and technological factors should accelerate growth in the market for medical therapies to treat urological disorders, particularly in our product categories. These factors include the following:
? Aging population. The incidence of urological disorders increases with age. The over-40 age group in the United States is growing almost twice as fast as the overall population. Accordingly, the number of individuals developing urological disorders is expected to increase significantly as the population ages and as life expectancy continues to rise.
? Increased consumer awareness. In recent years, the publicity associated with new technological advances and new drug therapies has increased the number of patients visiting their urologists to seek treatment for urological disorders.
--------------------------------------------------------------------------------
Urigen's two clinical stage products target significant unmet medical needs with meaningful market opportunities in urology:
URG101, a bladder instillation for Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)
URG301, a female urethral suppository for urethritis and nocturia
URG101 targets Painful Bladder Syndrome/Interstitial Cystitis ("PBS" or "PBS/IC") which affects approximately 10.5 million men and women in North America. URG101 is a unique, proprietary combination therapy of components that is locally delivered to the bladder for rapid relief of pain and urgency as demonstrated in Urigen's positive Phase II Pharmacodynamic Crossover study.
URG301 targets urethritis and nocturia, typically seen in overactive bladder patients. URG301 is a proprietary dosage form of an approved drug that is locally delivered to the female urethra. Urethritis pain commonly occurs with urinary tract infections (UTIs) which cause more than 8 million visits to the doctor annually. Nocturia, or nighttime urgency and frequency, is secondary to overactive bladder and can severely impact quality of life by disrupting the normal sleep pattern.
The novel urethral suppository platform presents excellent opportunities for effective product lifecycle management. As market penetration of URG301 deepens, line extensions will be available through alternate generic drugs as well as new chemical entities. To further expand the pipeline, the Company will identify and prioritize both marketed and development-stage products for acquisition. The commercial opportunity for such candidates will benefit significantly from the synergy provided by URG101 and URG301 in the urology marketplace.
We are seeking a world wide partner for URG101 to complete it's development and commercialization. We had planned to market our products to urologists and urogynecologists in the United States via a specialty sales force managed internally.
POTENTIAL PRODUCTS, TECHNOLOGIES AND SERVICES
Following is a description of our products currently in development, the anticipated market for such products as well as the competitive environment in these markets.
Proprietary Product Candidates:
URG101
Market Opportunity for Treatment of Painful Bladder Syndrome
Presently, no approved products exist for treating PBS, and those that have been approved for interstitial cystitis, a subset of PBS, are based on clinical studies which have shown the drugs to be marginally effective. According to its website, the FDA has approved two drugs for the treatment of interstitial cystitis and neither is labeled as providing immediate system relief. For example, at three months, the oral drug Elmiron achieved a therapeutic benefit in only 38% of patients on active drug versus 18% on placebo. The other drug approved for interstitial cystitis, RIMSO?-50 is an intravesical treatment that was not based on double-blind clinical trial results. According to the Interstitial Cystitis Data Base Study Experience published in the year 2000, RIMSO?-50 is widely recognized as ineffective and not included among the top ten most common physician-prescribed treatments for urinary symptoms.
Consequently, there remains a significant need for new therapeutic interventions such as URG101 that can address the underlying disease process while also providing acute symptom relief. PBS is a chronic disease characterized by moderate to severe pelvic pain, urgency, urinary frequency, dyspareunia (painful intercourse) with symptoms originating from the bladder. Current epidemiology data shows that PBS may be much more prevalent than previously thought.
One theory of PBS's pathological cause implicates a dysfunction of the bladder epithelium surface called the urothelium. Normally, the urothelium is covered with a mucus layer, the glycosaminoglycan, or GAG, layer, which is thought to protect the bladder from urinary toxins. A deficiency in the GAG layer would allow these toxins to penetrate into the bladder wall activating pain sensing nerves and causing bladder muscle spasms. These spasms trigger responses to urinate resulting in the symptoms of pelvic pain, urgency and frequency, the constellation of symptoms associated with this disease. Once established, PBS can be a chronic disease, which can persist throughout life and can have a devastating impact on quality of life.
In May of 2009, the RAND Corporation reported a survey of 100,000 households in the U.S. and estimated that there are 3.4 to 7.9 million women in the U.S. with interstitial cystitis. We had estimated that the prevalence of PBS in North America to be 10.5 million, of which 3.8 million would experience severe enough symptoms to be classified as having interstitial cystitis, a subset of PBS. This estimate was based on studies conducted by Clemens and colleagues at Northwestern University and by Drs. Matt T. Rosenberg and Matthew Hazzard at the Mid-Michigan Health Centers. Each group independently concluded that the number of subjects with interstitial cystitis has been significantly underestimated. They evaluated over 1,000 female primary care patients over the course of a year using a pain, urgency/frequency questionnaire to categorize subjects as symptomatic or not. We calculated the North America PBS population based on a cutoff score of 13 on the pain, urgency/frequency scale, and assumed a ratio of 1:2 for men to women; and for interstitial cystitis population we used a more stringent cutoff score of 15.
--------------------------------------------------------------------------------
Product Development
We have licensed the URG101 technology from the University of California, San Diego. The license agreement is exclusive with regard to patent rights and non-exclusive with regard to the written technical information. We may also grant a sublicense to third parties. Pursuant to the license agreement, which was effective as of January 18, 2006, we were required to pay a license issue fee in the form of 7.5% of Urigen N.A. authorized common stock, and we were required to pay (i) license maintenance fees of $15,000 per year which was amended on December 22, 2008 as follows: (a) $5,000 payable on May 6, 2009, (b) $15,000 payable on June 6, 2009, $20,000 payable on June 6, 2010 and $25,000 payable on June 6, 2011 and annually thereafter on each anniversary until the Company is commercially selling the licensed product. On August 24, 2009, the license maintenance fees were amended again to provide (a) partial consideration and in lieu of cash for license maintenance fees that were due on May 6, 2009 and June 6, 2009, and require the Company to issue 250,000 shares of its common stock to the University, (b) $20,000 payable on June 6, 2010 and $25,000 payable on June 6, 2011 and annually thereafter on each anniversary until the Company is commercially selling the licensed product, (ii) milestone payments of up to $625,000 upon the occurrence of certain events related to FDA approval, (iii) an earned royalty fee equal to 1.5% to 3.0% of net sales, (iv) sublicense fee, if applicable, and (v) beginning in the year of any commercial sales, a minimum annual royalty fee of $35,000. The term of the license agreement ends on the earlier of the expiration date of the longest-lived of the patent rights or the tenth anniversary of the first commercial sale. Either party may terminate the license agreement for cause in the event that the other party commits a material breach and fails to cure such breach. In addition, we may terminate the license agreement at any time and for any reason upon a 90-day written notice. In the event that any licensed product becomes the subject of a third-party claim, we have the right to conduct the defense at our own expense, and may contest or settle claims in our sole discretion; provided, however, that we may not agree to any settlement that would invalidate any valid claim of the patent rights or impose any ongoing obligation on the university. Pursuant to the terms of the license agreement, we must indemnify the university against any and all claims resulting or arising out of the exercise of the license or any sublicense, including product liability. In addition, upon the occurrence of a sale of a licensed product, application for regulatory approval or initiation of human clinical trials, we must obtain and maintain comprehensive and commercial general liability insurance.
The individual components of this combination therapy, lidocaine and heparin, were originally approved as a local anesthetic and an anti-coagulant, respectively. It was demonstrated that a proprietary formulation of these components reduced symptoms of pelvic pain and urgency upon instillation into the bladder.
The rationale for this combination therapy is two-fold. The lidocaine is a local anesthetic that reduces the sensations of pain, urge and muscle spasms. The heparin, a glycosaminoglycan, coats the bladder wall augmenting natural heparinoids, which may be deficient on the surface of the urothelium. Heparin is not being utilized in this application for its anti-coagulant properties. Heparinoids comprise part of the mucus layer of the urothelium and help to limit urinary toxins from penetrating the underlying tissues thereby preventing pain, tissue inflammation and muscle spasms.
Clinical Trial Status
Urigen filed an investigational new drug application ("IND") in 2005 and has undertaken two (2) clinical studies to date: URG101-101 and URG101-104. The results of the most recent study, URG101-104, have been announced with primary and secondary endpoints all achieving statistical significance. The URG101-104 study was designed using lessons learned from the URG101-101 study which did not achieve statistical significance on the primary endpoint at 3 weeks, but did demonstrate that the URG101 product was safe and resulted in an acute reduction in urgency (P=0.006) and trend towards reduction in bladder pain (P=0.093).
The URG101-104 study was a pharmacodynamic crossover study to evaluate the time course of response to URG101 drug and placebo in subjects experiencing acute symptoms of painful bladder syndrome/interstitial cystitis. In March 2008 an un-blinded interim analysis was conducted. Primary and secondary efficacy measurements in the study demonstrated that URG101 was significantly better than placebo. Top line data analysis findings include: primary endpoint - improvement in average daytime pain (p=0.03); secondary endpoints - improvement in daytime urgency (p=0.03), total symptom score (p=0.03), improved overall symptom relief as measured by PORIS (p=0.01).
Competitive Landscape
PBS is currently an underserved medical market. There is no acute treatment for pain of bladder origin other than narcotics. Currently, there are two approved therapeutics, RIMSO?-50 and Elmiron?, for the treatment of interstitial cystitis. Both of these approved products require chronic administration before any benefit is achieved. Other non-approved therapies provide marginal, if any benefit.
Development of drugs for PBS/IC has targeted a wide array of potential causes with limited success. We believe that URG101 will be well positioned, as it will address both the acute pain the patient experiences and the dysfunctional aspect of the urothelium of the bladder wall.
--------------------------------------------------------------------------------
Commercialization Plan
Remaining a virtual company, Urigen will commercialize URG101 in the United States by collaborating with appropriate commercial partners and vendors to conduct a situational analysis of the United States; develop an appropriate product strategy; and then, create and implement a launch plan.
As appropriate, co-promotional agreements will be established with interested parties to ensure that URG101 is adequately promoted to the entire U.S. healthcare community. In all countries outside the United States, Urigen will either assign licensing rights to or establish Supply and Distribution Agreements with interested parties. Initial discussions to acquire such rights have begun with interested parties who have a strategic interest in Urology and Painful Bladder Syndrome, and have the requisite infrastructure and resources to successfully commercialize URG101.
Manufacturing of URG101 finished goods kits will be conducted by contract manufacturers approved by regulatory authorities and with a history of having demonstrated an ability to support a global supply chain demand. Negotiations with such manufacturers are in progress to establish requisite manufacturing and supply agreements.
URG301
Market Opportunity for Treatment of Urethritis and Nocturia
A significant percentage of female patients presenting with Urinary Tract Infections (UTI) and Painful Bladder Syndrome have a substantial urethral component to their disease. There are approximately 8 million doctor visits annually for urinary tract infections alone. The severity of their urethral pain and discomfort may compromise the administration of intravesical therapies while the antibiotics used to treat their UTI do not address their urethral pain. To overcome this problem, Urigen is developing a urethral suppository to resolve this pain and discomfort.
Nocturia, frequent nighttime urination, is a symptom of an underlying condition or disease, such as PBS. A poll conducted by the National Sleep Foundation in 2003 reported that nearly two-thirds of adults between the ages of 55 and 84 suffered from nocturia. The International Continence Society defines nocturia as two or more night time voids. In its simplest terms, nocturia refers to urination at night and entails some degree of impairment, with urinary frequency often considered excessive and disruptive. Patients with severe nocturia may get up five or more times per night to go to the bathroom to void.
Preliminary work, by Kalium, Inc., from which we licensed the product, has been conducted to test a variety of generally recognized as safe ("GRAS") approved carriers and therapeutic agents as well as to optimize melt times for the suppository. Additionally, patients with urethritis were offered the use of a suppository that contained lidocaine and heparin for the treatment of their symptoms of urethral pain and inflammation. An optimized formulation has been tested in an open-label clinical trial. This study was undertaken to determine the proportion of urethral symptoms by 50% or more in patients with urethritis. Results were evaluated 15 minutes after administration of the suppository using the patient overall rating of improvement of symptoms ("PORIS") scale. The result of this pilot Phase II (open label) study in approximately 30 patients demonstrated a 50% or greater improvement in 83% of patients experiencing pain and 84% of patients experiencing urgency related to urethritis following a single treatment. Importantly, 50% of patients had complete resolution of pain and 63% had complete resolution of urgency. Duration of relief following a single treatment was greater than 12 hours in approximately 30% of subjects. This testing was not performed as a formal clinical trial, but under physician care and information provided to us from Kalium, Inc. Clinical development of URG301 will be similar to that of lidocaine jelly which is approved for urethritis.
The licensed patents cover a range of active ingredients that can be formulated in the suppository to create a desired therapeutic effect. Such agent may include antibiotics, antimicrobials, antifungals, analgesics, anesthetics, steroidal anti-inflammatories, non-steroidal anti-inflammatories, mucous production inhibitors, hormones and antispasmodics.
Market Opportunity for Treatment of Overactive Bladder ("OAB")
According to an article published by the Mayo Foundation for Medical Education and Research, overactive bladder is a fairly common malady as approximately 17 million individuals in the United States and more than 100 million worldwide are afflicted. Importantly, the condition worsens as people age.
Although not life-threatening, for the individual overactive bladder is inconvenient, potentially embarrassing, and may disrupt sleep; while significantly impacting quality of life. Frequently these individuals are afraid to leave their home, or are unable to participate in a lengthy meeting, dinner, or social event. Unfortunately, many of these people hesitate to seek treatment because they think their symptoms are a normal part of aging. This mindset is incorrect as overactive bladder is not normal, is treatable, and treatment can significantly ease symptoms and improve quality of life.
Patient compliance studies report that more than half of patients taking an oral OAB drug stop taking it within six months of initiation of therapy. Such studies also report that only 10 to 20 percent of people remain on an oral OAB medicine six to 12 months after initiating treatment. About a third to one-half of those who discontinue their drug therapy do so due to side effects, they simply can not tolerate the drug or do not find the minimal benefit they receive to outweigh the negative effects of the drug.
Manufacturers of these overactive bladder therapies have expended significant research energy and money in their efforts to reduce side effects to increase patients' adherence to treatment. However, some physicians, experts and healthcare providers do not believe that the marginal benefits of these oral agents outweigh the significant side effects endured by patients prescribed such drugs.
--------------------------------------------------------------------------------
Importantly, given these efficacy and side effect limitations, the overactive bladder market has experienced significant and constant
double digit annual growth. According to sales data provided by the four largest U.S. pharmaceutical companies in their annual reports, we estimate that in the five year period 2000 through 2004, sales of OAB drugs in the United States grew from $636 million to more than $1.3 billion, and year over year percentage increases for this five year period were 40%, 25%, 18%, and 13%, respectively.
Product Development
We are developing an IND to initiate an exploratory study to evaluate the safety and efficacy of an intraurethral suppository to treat urethritis, nocturia and the symptoms of acute urinary urgency associated with overactive bladder. The study will enroll subjects randomized to drug vs. placebo in a 1:1 ratio to evaluate the safety and efficacy of URG301 for one or more of these disorders.
Commercialization Plan
Although we are seeking a world wide partner for URG101, we will commercialize URG301 in the United States by conducting a situational analysis of the United States; developing an appropriate product strategy; and then, creating and implementing a launch plan that incorporates the 75 to 100 member sales organization that we are planning to establish for the launch of URG101. As appropriate, co-promotional agreements will be established with interested parties to ensure that URG301 is adequately promoted to the entire U.S. healthcare community.
In all countries outside the United States, Urigen will either assign licensing rights to or establish Supply and Distribution Agreements with interested parties. Discussions to acquire such rights will be scheduled with interested pharmaceutical companies who have a strategic interest in Incontinence and Overactive Bladder, and have the requisite infrastructure and resources to successfully commercialize URG301.
Competitive Landscape
Approved prescription drugs used to treat overactive bladder are not optimally effective and have side effects that can limit their use. These approved drugs-oxybutynin (Ditropan?, Ditropan XL? and Oxytrol?, a skin patch); tolterodine (Detrol?, Detrol LA?); trospium (Sanctura?); solifenacin (Vesicare?); and darifenacin (Enablex?)-demonstrate remarkably similar efficacy.
However, they do differ in the side effects they cause and their cost. Side effects include dry mouth, constipation, and mental confusion. In clinical studies, Ditropan XL, Detrol LA, Oxytrol, Sanctura, Vesicare, and Enablex have caused fewer side effects than the short acting dosage forms of oxybutynin (Ditropan) and tolterodine (Detrol).
Oxybutynin has been available since 1976 and tolterodine since 1998. The short-acting form of oxybutynin is available as a less expensive generic drug while the extended-release formulations of both oxybutynin and tolterodine are available, but not as generics. An oxybutynin patch (Oxytrol) was launched in 2003 while solifenacin and darifenacin were introduced in 2004.
Retail prices for these products vary considerably and are tied directly to the number of pills taken per day and whether or not the product is available generically. The least expensive is generic oxybutynin 5mg with an average monthly cost of $20 compared to Ditropan 5mg at $79 and Ditropan XL 5mg costing $122 per month on average. The average monthly cost for Detrol is $138; Detrol LA $119; Sanctura $116; Vesicare $121; and Enablex $116. (Prices from May 2006 Wolters Kluwer Health, Pharmaceutical Audit Suite).
CORPORATE COLLABORATIONS
We retained Navigant Consulting, Inc. to conduct a situational assessment of physicians, healthcare payers and patient advocacy groups to generate a product strategy that addressed key geographical markets, customers, product positioning, lifecycle management and pricing. The project cost of this first phase was $125,000, of which $86,000 had been paid through September 30, 2009.
Life Science Strategy Group LLC (LSSG) was retained to create and implement a commercialization plan specific for us in the United States. Pursuant to the terms of the agreement, LSSG billed us for all professional services at established hourly rates, plus related out-of-pocket expenses. Payment of invoices is not contingent upon results. LSSG may terminate the agreement if payment of fees is not made within 45 days of receipt of the invoice. There is no definitive termination date of the agreement, but the estimated timing for all of the projects ranges from 30 to 42 months. As appropriate, co-promotional agreements will be established with interested parties to ensure that URG101 is adequately promoted to the entire United States healthcare community. As of September 30, 2009 LSSG had invoiced the Company $28,000 of which $3,000 was paid in cash. LSSG principals agreed to accept 147,059 shares of subscribed common stock at $0.17 per share in lieu of the remaining $25,000.
--------------------------------------------------------------------------------
We also have two license agreements pursuant to which we license certain patent rights and technologies:
In January 2006, Urigen N.A. entered into an asset-based transaction agreement with a related party, Urigen, Inc. Simultaneously, Urigen N.A. entered into a license agreement with the University of California, San Diego ("UCSD"), for certain patent rights. In exchange for this license, Urigen N.A. issued 1,846,400 common shares and is required to make annual maintenance payments of $15,000 which was amended on December 22, 2008 as follows: (a) $5,000 payable on May 6, 2009, (b) $15,000 payable on June 6, 2009, (c) $20,000 payable on June 6, 2010 and (d) $25,000 payable on June 6, 2011 and annually thereafter on each anniversary until the Company is commercially selling the licensed product, and . . .
Hello,
Q If the numbers were good the price would rise, higher taxes, at least the super MM. No news today, woeful already thought of a notice of the numbers ... grasses have been grown and then?? has already been harvested?
, Sold for feeding??
Sales of batteries?
It will soon end the salaries must be paid back.
Nothing bad here think!
Fir
From Yahoo - Board
http://www2.greenpowerconferences.co.uk/v8-12/Prospectus/Index.php?sEventCode=BN0911US # Meet
NEWS !
VIASPACE to Present at Next-Generation Biofuels Feedstocks USA Conference
2009-11-12 08:30 ET - News Release
IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- VIASPACE Inc. , a clean energy company growing Giant King(TM) Grass as a renewable, low carbon, energy crop, today announced that Chief Executive Dr. Carl Kukkonen will make a presentation on Giant King Grass at the Next-Generation Biofuels Feedstocks USA Conference to be held November 16-17, 2009, at Le Meridien Hotel in San Francisco.
The conference - to identify renewable energy feedstocks with the most potential - will be attended by leading experts, business executives, investors and others to discuss the challenges and opportunities in next-generation biofuels feedstocks. The conference will compare how existing and next-generation feedstocks impact the environment and greenhouse gas emissions. Prices, market trends and yield potential will also be discussed.
VIASPACE Chief Executive Dr. Carl Kukkonen remarked: "Whether biomass is used to generate electricity or as feedstock for producing green gasoline, price, supply reliability, technical performance and environmental effects are critical issues. We feel that, in general, dedicated energy crops grown specifically for use as feedstock can meet the needs of energy producers. The very high yield and verified technical performance of Giant King Grass make it a highly competitive and economically advantageous energy crop. As a result we are seeing increasing interest in our Giant King Grass and are in discussions to establish long-term supply agreements."
Kukkonen said that, from a business standpoint, even a relatively small 30-megawatt (MW) biomass-dedicated power plant would use 175,000 tons of Giant King Grass each year and potentially generate $6.3 million in grass sales. A much larger 2,000-MW coal-fired power plant, by replacing only 20% of its coal with Giant King Grass pellets, would require approximately 2.3 million tons of grass pellets per year, representing sales of approximately $230 million. Both projections are based on current prices for biomass and pellets.
About VIASPACE Inc.
VIASPACE is an alternative energy company providing products and technology for renewable and clean energy that reduce or eliminate dependence on fossil and high-pollutant energy sources. The Company provides raw material for cellulosic biofuels and develops and markets fuel cell cartridges, products and technology. VIASPACE subsidiary Direct Methanol Fuel Cell Corporation owns a portfolio of fuel cell patents licensed from Pasadena-based California Institute of Technology (Caltech), which manages NASA's Jet Propulsion Laboratory, where the direct methanol fuel cell was invented. For more information, please see www.VIASPACE.com or contact Dr. Jan Vandersande, Director of Communications, at 800-517-8050 or IR@VIASPACE.com.
Safe Harbor Statement: Information in this news release includes forward-looking statements. These forward-looking statements relate to future events or future performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such factors include, without limitation, risks outlined in our periodic filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K for the year ended December 31, 2008, as well as general economic and business conditions; the ability to acquire and develop specific products and technologies; changes in consumer and business demand for the Company's products; competition from larger companies; changes in demand for alternative and clean energy; risks associated with international transactions; risks related to technological change; and other factors over which VIASPACE has little or no control.
VIASPACE Inc.
CONTACT: Dr. Jan Vandersande, Director of Communications of VIASPACE Inc.,
1-800-517-8050, IR@VIASPACE.com.
The same procedure is in the U.S. as in Germany.
So you will not get rich quick on the exchange.
The thoughts may all be well and good but if no money is there
The course will stay down.
Of course VSPC can be a big flyer but will still belong to our previously
Patience will be played.
I watch the last 3 years VSPC have a lot of shares in the German forum and have been a lot of squads and collected. / Walstreet online)
For 3 years VSPC is like.
I am still waiting for contracts, the money to bring a nasty sales and profits. Until now there was only talk and no profits.
I hope that soon will arrive in the news tells of profits
lengthy contracts, and finally designated large companies.
Good luck
Who here still says there is no dilution,
Shares will be on the market including 100 K threw blocks.
Those familiar Schmeister not buy it, here is only thrown is called dilution.
Until then
Fir
In any case, all are not price-sensitive news and have nothing to say about time, since the MM has a number of games in stock.
Fir
VSPC is bought at the top then falls again.
Here is clearly Dillution underway.
Too bad every news was so far.
Fir
A weak news.
However VSPC has increased ever forcibly at a news except when she announced that she does with Samsnung shops.
What is missing are as still winning numbers and statements from outside the Q.
Here patience is announced, I'm here for 3 years have a lot of shares and
Will continue to wait. Moreover, we know that yes, the salaries of CEOs should be paid for.
Dillution is probably still at work.
Fir
VIASPACE to Trademark Giant King(TM) Grass
2009-11-10 08:30 ET - News Release
IRVINE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- VIASPACE Inc. , a clean energy company growing Giant King(TM) grass as a renewable, low carbon, energy crop, today announced it has applied to the U.S. Patent and Trademark Office to trademark "Giant King" as a unique brand of grass.
Interest in, and demand for, Giant King grass is growing, as energy producers seek next-generation feedstock for biofuel to reduce dependence on high-polluting fossil fuels and biomass for replacing coal in electric power plants. Due to advantageous growing characteristics and superior technical performance of Giant King grass, compared to other agricultural feedstock now being used for a biofuels and biomass, VIASPACE sees substantial business potential in establishing Giant King grass as the leading brand for renewable energy feedstock.
VIASPACE Chief Executive Dr. Carl Kukkonen stated: "VIASPACE has created global interest in Giant King grass, and it is becoming apparent that its unique characteristics and tested performance provide a strong basis for establishing Giant King grass as the leading source of low-carbon renewable energy. We believe a trademark will not only reinforce the competitive advantages and value of Giant King grass, but also prevent others from exploiting the name and buzz that Giant King grass is creating."
About VIASPACE Inc.
VIASPACE is an alternative energy company providing products and technology for renewable and clean energy that reduce or eliminate dependence on fossil and high-pollutant energy sources. The Company provides raw material for cellulosic biofuels and develops and markets fuel cell cartridges, products and technology. VIASPACE subsidiary Direct Methanol Fuel Cell Corporation owns a portfolio of fuel cell patents licensed from Pasadena-based California Institute of Technology (Caltech), which manages NASA's Jet Propulsion Laboratory, where the direct methanol fuel cell was invented. For more information, please see www.VIASPACE.com or contact Dr. Jan Vandersande, Director of Communications, at 800-517-8050 or IR@VIASPACE.com.
Safe Harbor Statement: Information in this news release includes forward-looking statements. These forward-looking statements relate to future events or future performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such factors include, without limitation, risks outlined in our periodic filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K for the year ended December 31, 2008, as well as general economic and business conditions; the ability to acquire and develop specific products and technologies; changes in consumer and business demand for the Company's products; competition from larger companies; changes in demand for alternative and clean energy; risks associated with international transactions; risks related to technological change; and other factors over which VIASPACE has little or no control.
VIASPACE Inc.
CONTACT: Dr. Jan Vandersande, Director of Communications of VIASPACE Inc.,
1-800-517-8050, IR@VIASPACE.com
Web site: http://www.viaspace.com/
Hi from Germany,
Because I can only say the same thing you are Tommy Lesewurm name of this and allows us to participate. Thanks to you.
I work in an energy company that generates electricity and heat.
We also have wooden pallets in use, however, not grass.
In germany we still think a little bit conservative and is not as experimentfreudig.
However, since I'm working in a management position is superior to this.
Despite this, thank you so much good info here to see made available.
Greetings from Germany
Now....,,sorry
Good night..
http://access-wallstreet.com/11/06/2009/small-cap/30641/
Tanne
News:
http://www.qualitystocks.net/clients.php?clientid=vspc#head
Good night from germany
Tanne
Good morning to USA, here is in 2 hours evening...
Its nice to be here...
The 0,03$ is a wall....
good luck
Tanne
For sale only online.
Good luck!
Fir!
http://shop1048.jp/product/plist_category.aspx?id=A0D64C45-F807-4AC5-BB47-E9E988442E6E
Yes, there will be a moderate and a continuous increase.
Oh, the weather is rainy and 10 ° C warm. The autumn comes.
But the price of VIASPACE will be difficult to have come across the 0,03.
Would not be surprised if today we max. Make 10% +.
VIASPACE is a brand for himself.
Fir
It has been called today for the first time that Toshiba are already on sale, albeit in small numbers, but set on expansion.
The patent is still over thin cell phones and I-Pods, laptops and much more.
And two names has been clearly stated,,, Toshiba and Samsung as we have always known about this yet VGE ... ... ..
BID Manager Germany and the rise ...
Although there today and tomorrow should be no huge Kursprung. The course is set and it was confirmed today.
The big come on board,,,
Fir
Very good News,,, Samsung, Toshiba, DMFC...
Tanne
Micro Fuel Cell Technology Awarded U.S. Patent, Exclusively Licensed by Caltech to VIASPACE Subsidiary
2009-11-02 08:30 ET - News Release
IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- VIASPACE Inc. , an alternative energy company providing products and technology for renewable, clean energy, announced that new technology enabling fuel cells for micro applications has been patented under U.S. Patent Number 7,585,577 "Monopolar Fuel Cell Stack Coupled Together Without Use of Top or Bottom Cover Plates or Tie Rods."
The patent was issued to Caltech, which licensed it exclusively to VIASPACE subsidiary Direct Methanol Fuel Cell Corporation (DMFCC). The inventors are Sekharipuram R. Narayanan and Thomas I. Valdez, both with the NASA/Caltech Jet Propulsion Laboratory, where the direct methanol fuel cell was invented.
The new patent application is related to monopolar fuel cell stacks. Traditionally, direct fuel cells stacked unit cells vertically like slices of bread in a loaf. Monopolar stacks use the same unit cells, but the "bread slices" can be laid horizontally next to each other. This allows for a thinner fuel cell that is more suitable for many micro applications like mobile phones. The patent states that "the new stack design offers two-to-three fold improvement in power densities, suitable for manufacturing, uses inexpensive plastic materials, and straightforward to troubleshoot and assemble. Such a stack design will substantially improve the commercialization of portable direct methanol fuel cell power sources."
The new patent follows previously awarded U.S. Patent Number 6,680,139 "Reduced Size Fuel Cell for Portable Applications," and U.S. Patent Number 6,756,145 "Electrode and Interconnect for Miniature Fuel Cells Using Direct Methanol Feed."
VIASPACE and DMFCC Chief Executive Dr. Carl Kukkonen remarked: "This new patent adds significant value to our intellectual property portfolio. It will be difficult for any company to go to market with direct methanol fuel cells for micro applications, or other applications for that matter, without first obtaining protection under the Caltech patents which we have licensed."
Direct Methanol Fuel Cell Corporation holds an extensive and comprehensive portfolio of direct methanol fuel cell patents licensed from Caltech as well as the University of Southern California. The patents cover the direct methanol fuel cell concept, technology that makes the science practical for use, and important processes related to manufacturing. Several patents are considered fundamental and blocking.
"Direct Methanol Fuel Cell Corporation is focusing on disposable fuel cartridges that provide the fuel source for direct methanol fuel cells," Kukkonen stated. "As previously announced, we are partnered with Samsung and are also working under confidentiality agreements with other companies. Strategically, we are engaging in opportunities to apply our intellectual property and patents in order to help develop the direct methanol fuel cell market."
In a related development, on October 22, 2009, IDG News Service reported that "After years of prototypes and promises that the technology was just around the corner, Toshiba has become the first major consumer electronics maker to launch a device using direct methanol fuel cell (DMFC) technology. The Dynario, a charger that can replenish [recharge] the batteries in gadgets like cell phones and digital cameras via USB, went on sale on Thursday on Toshiba's Web store. The charger is about the same thickness and width as a cell phone, although it is slightly longer than most phones at 15 centimeters. A single 50-milliliter charge of methanol will enable it to recharge a cell phone twice. The next step for Toshiba will be gadgets with embedded fuel cells. Earlier this month at Ceatec 2009 one of its DMFCs was on display inside a cellular telephone but both Toshiba and Japanese carrier KDDI, which was demonstrating the phone, gave no estimate for its release. Toshiba didn't disclose any plans to sell the charger overseas."
To date, Caltech's direct methanol fuel cell patents have been issued in the United States, Korea and other countries but not yet in Japan.
About VIASPACE Inc.
VIASPACE is an alternative energy company providing products and technology for renewable and clean energy that reduce or eliminate dependence on fossil and high-pollutant energy sources. The Company provides raw material for cellulosic biofuels and develops and markets fuel cell cartridges, products and technology. VIASPACE subsidiary Direct Methanol Fuel Cell Corporation owns a portfolio of fuel cell patents licensed from Pasadena-based California Institute of Technology (Caltech), which manages NASA's Jet Propulsion Laboratory, where the direct methanol fuel cell was invented. For more information, please see www.VIASPACE.com or contact Dr. Jan Vandersande, Director of Communications, at 800-517-8050 or IR@VIASPACE.com.
Safe Harbor Statement: Information in this news release includes forward-looking statements. These forward-looking statements relate to future events or future performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such factors include, without limitation, risks outlined in our periodic filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K for the year ended December 31, 2008, as well as general economic and business conditions; the ability to acquire and develop specific products and technologies; changes in consumer and business demand for the Company's products; competition from larger companies; changes in demand for alternative and clean energy; risks associated with international transactions; risks related to technological change; and other factors over which VIASPACE has little or no control.
VIASPACE Inc.
CONTACT: Dr. Jan Vandersande, Director of Communications, +1-800-517-8050,
IR@VIASPACE.com
Web site: http://www.viaspace.com/
Hi from germany.
Fun Fun Fun...
tanne
Hello together,
'm From 3.5 years at VSPC. Whenever it was assumed the price would rise again, he has fallen.
Well again, the optimists in the market but hopes that the price of a sustained rise time is small.
VSPC has reinstecken a good marketing but no investors, the time a lot of money.
Until this happens is not going to happen.
Now there's VGE, filings are written quickly, quickly made dilutions. The number of shares will eventually be more than 1 billion then there is only one split on noti
VSPC will rise but not as we hope it all. Far from it.
If I am wrong you can go all on me.
Tanne
Samsung and Toshiba?
Samsung has indeed now been confirmed that they use parts of fuel cells VSPV. Dr K's CEO VSPC already had many messages from the development partners and admit that you never told the name because of the distortion of competition and told not to report to hire on unhatched eggs.
The cycle is slow and last of all this now is still the grass, the daughter of VSPC.
Here a meltdown, though slow and where we still need some patience. I am from Germany for 3.5 years, and hold shares of VSPC have followed everything and see a Massive expansion in mind!
Good luck!
Hello together!
I post from Germany, and am heir to VIASPACE has invested 3.5 years! Because of my conviction I have ever later purchased and now have an adequate EK. The story has developed further and I will be very glad that I can sit back and slowly myself zuesehen shall go like the course.
Chart-see it here, excellent, and the number of users here has increased nicely.
Pellets seems to be the magic word, and here in Germany there are wooden. VIASPACE has now fuel cells in the luggage and it seems to me a rießengroßes Gesachäft to werden.Bei the Chinese vorscihtig because I am always able to turn everything into windeseiel again. But the environment will prevail and there VIASPACE is still small in a few years, but quite large. Well here are so many Viaspacler and let us work together to help this company take all up.
Greeting